Home >> IPO >> Speciality Medicines IPO : GMP, Price, Analysis, And Details
Speciality Medicines IPO : GMP, Price, Analysis, And Details
Table of Contents
- Speciality Medicines IPO- Company Analysis
- Speciality Medicines IPO Details
- Company Financials
- The Objective of the Issue
- Listed Peers of Speciality Medicines Ltd.
- Evaluation of P/E Ratio
- IPO's Strengths
- IPO's Weaknesses
- Speciality Medicines IPO GMP (Grey Market Premium)
- Speciality Medicines IPO Summary
- Speciality Medicines IPO Allotment Status
- Promoters And Management of Speciality Medicines Ltd.
- IPO Lead Managers
- Dividend Policy
- Conclusion
Speciality Medicines IPO- Company Analysis
Speciality Medicines IPO under the SME IPO category is a bookbuild issue of Rs. 29.14 Cr by Speciality Medicines Limited and is involved in the marketing and distribution of completed specialty pharmaceutical formulations in both local and foreign markets, including expensive oral and injectable drugs used to treat complicated chronic illnesses.
A variety of specialty pharmaceutical finished formulation products, including tablets, capsules, creams, syrups, eye drops, gels, infusions, inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, sachets, and suspensions, are offered in the company's portfolio.
The company uses two business models:
(a) marketing and distribution of procured specialty pharmaceutical goods, and
(b) contract manufacture of completed formulations for global distribution.
Speciality Medicines IPO Details
The Speciality Medicines IPO date of opening is 20 Mar 2026, its initial public offering will end on 24 Mar, IPO allotment on Mar 25 and refund initiation on Mar 27, 2026.
The Rs. 29.14 crore new SME IPO comprises a wholly fresh issue of 0.24 crore shares.
The Speciality Medicines IPO listing date (expected) might be on Monday, Mar 30 2026, and listing at the BSE and SME.
The Speciality Medicines IPO price band is Rs. 117 to Rs. 124.
IPO Timetable (Tentative)
|
Events |
Date |
|
IPO Opening Date |
Mar 20, 2026 |
|
IPO Closing Date |
Mar 24, 2026 |
|
IPO Allotment Date |
Mar 25, 2026 |
|
Refund Initiation |
Mar 27, 2026 |
|
IPO Listing Date |
Mar 30, 2026 |
Click to open demat account and apply for the IPO.
Company Financials
(Amount in Cr)
|
Particulars |
31 Mar 2025 |
31 Mar 2024 |
31 Mar 2023 |
|
Assets |
45.57 |
39.98 |
22.68 |
|
Total Income |
36.93 |
58.54 |
27.66 |
|
Profit After Tax |
6.06 |
8.61 |
2.93 |
|
EBITDA |
6.51 |
9.09 |
5.26 |
|
Net Worth |
36.47 |
30.42 |
15.06 |
|
Reserves and Surplus |
30.04 |
23.98 |
9.95 |
|
Total Borrowing |
4.81 |
5.05 |
2.86 |
Cash Flows
(Amount in lac)
|
Net Cash Flow |
31 Mar 2025 |
31 Mar 2024 |
31 Mar 2023 |
|
Net Cash Flow Operating Activities |
(579.44) |
(480.02) |
(365.31) |
|
Net Cash Flow Investing Activities |
(206.90) |
(2.52) |
(11.80) |
|
Net Cash Flow Financing Activities |
846.01 |
481.28 |
387.50 |
Revenue Bifurcation
(Rs. in Lac)
(Source: RHP)
The Objective of the Issue
The company desires to use the Net Proceeds from the Issue to fulfill its following goals:
-
Marketing and Advertising Expenditure. ~ Rs. 1.66 Cr.
-
Setting up of Research and Development (R&D) Centre at Revenue City, Dist. Valsad, Gujarat. ~ Rs. 12.68 Cr.
-
Product Registration in International Markets and Product Development for sale in international markets. ~ Rs. 2.99 Cr.
-
Working Capital Requirements. ~Rs. 8.00 Cr.
-
General Corporate Purposes.
Listed Peers of Speciality Medicines Ltd.
|
Name of Company |
Face Value (₹) |
Basic EPS (₹) |
PE Ratio (x) |
|
Remus Pharmaceuticals Limited |
10 |
65.21 |
10.41 |
|
Trident Lifeline Limited |
10 |
10.22 |
27.00 |
|
Mono Pharmacare Limited |
10 |
1.75 |
7.49 |
Valuation
|
KPI |
Value |
|
ROE |
37.85% |
|
ROCE |
33.39% |
|
Debt/Equity |
0.17 |
|
RoNW |
28.30% |
|
PAT Margin |
14.77% |
|
EBITDA Margin |
15.60% |
|
Price to Book Value |
2.62 |
Evaluation of P/E Ratio
Considering the period ended on FY 2025 with an EPS of Rs. 14.10 from the last year, the resulting P/E ratio is 8.79x.
Explore the Striders Impex IPO.
IPO's Strengths
-
Diverse worldwide presence
-
A wide range of products
-
Long-term customer relationship
-
Skilled promoters and management group.
IPO's Weaknesses
-
Supplier Dependency Risk
-
Quality Compliance Risk
-
R&D Capability Risk.
Speciality Medicines IPO GMP (Grey Market Premium)
Speciality Medicines IPO GMP today has not started yet, as of 18 Mar 2026 while writing this information.
Speciality Medicines IPO Summary
|
IPO Opening & Closing Date |
20 Mar, 2026 to 24 Mar, 2026 |
|
Face Value |
Rs. 10 per Share |
|
Issue Price |
Rs. 117 to Rs. 124 per Share. |
|
Lot Size |
1000 Shares |
|
Issue Size |
23,50,000 Shares (Rs. 29 Cr) |
|
Offer for Sale |
- |
|
Fresh Issue |
23,50,000 Shares (Rs. 29 Cr) |
|
Listing at |
BSE, SME |
|
Issue Type |
Bookbuild issue IPO |
|
Registrar |
Skyline Financial Services Pvt. Ltd. |
IPO Lot Details
Retail investors can invest in a minimum and maximum of 2 Lots (2000 Shares) for Rs. 2,48,000, and in multiples thereof, while HNI investors can invest in a minimum of 3 Lots (3000 Shares) for Rs. 3,72,000.
|
Minimum Lot Investment (Retail) |
2 Lots |
|
Maximum Lot Investment (Retail) |
2 Lots |
|
HNI (Min) |
3 Lots |
Speciality Medicines IPO Allotment Status
To check the Speciality Medicines IPO Allotment Status, visit the official Registrar’s website or BSE website. Below are the website links for you.
Using BSE Website - BSE IPO allotment status
Promoters And Management of Speciality Medicines Ltd.
-
Parth B Goyani
-
Goyani Sumit Babubhai.
|
Pre-Issue Promoter Shareholding |
59.67% |
|
Post-Issue Promoter Shareholding |
- |
IPO Lead Managers
Unistone Capital Pvt. Ltd.
Dividend Policy
The company has not paid a dividend during the last three years.
Conclusion
With a fair valuation (P/E ~8.79x), a robust ROE (~37.85%), minimal debt, and a varied product portfolio aimed at chronic conditions worldwide, the Specialty Medicines IPO offers an opportunity in the specialty pharmaceuticals industry. The money set aside for R&D, overseas registrations, and marketing puts it in a strong position for expansion in high-margin formulations despite concerns like supplier dependency and regulatory compliance.
Finowings IPO Analysis
Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO.
You must consult your financial advisor before making any financial decisions.
To Apply for the IPO, Click Here.
To Read the Prospectus of the Company Click Here to Download the DRHP.
Click Here To Stay Updated With The Upcoming IPOs.
DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.
.webp)
